Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,238.9
7.0 (0.22%)

 

  • STI Straits Times Index
    3,238.9
    7.0 (0.22%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,594.8
    1.2 (0.08%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,326.7
    3.0 (0.01%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,891.3
    -18.5 (-0.64%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,303.3
    161.8 (0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,128.3
    29.4 (0.48%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,162.2
    22.9 (1.07%)
    Index delayed 20 minutes
  • XAO XAO
    6,898.9
    58.1 (0.85%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,681.9M
  • Value: 1,310.8M
  • Rise: 177
  • Fall: 153
  • Unch: 499

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
SinoCloud0.001-
United Engineers2.700-0.010
YZJ Shipbldg SGD1.000+0.030
SingTel3.180-0.120
Golden Agri-Res0.255+0.010
Rex Intl0.191-0.007
China Star Food0.030+0.002
Tritech0.032+0.003
Ascendas Reit2.890-0.010
Sino Grandness0.044-

World Indices

World Indices
Name Last Change
Nasdaq 8,540.8 +61.8
HSI 26,326.7 +3.0
HSCEI 10,424.8 -2.6
Jakarta 6,128.3 +29.4
Nikkei 225 23,303.3 +161.8
SSE Comp 2,891.3 -18.5
Shanghai A 3,029.3 -19.4
Shanghai B 255.2 -3.0
PSE Comp 0.0
KOSPI 2,162.2 +22.9

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 15 Nov 2019 07:12
Last (SGD): 79.970 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 10.43523 Trailing EPS (SGD) e 8.57097 NAV (SGD) b 115.3124
PE a 7.663 Trailing PE f 9.330 Price / NAV b 0.6935
Dividend (SGD) d 3.811500 Cash In Hand (SGD) g 7.7136 Issued & Paid-up Shares c 74,246,000
Dividend Yield (%) d 4.766 Price / Cash In Hand g 10.367 Treasury Shares h 223,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,937.453
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,711.861
Piotroski F Score 7 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.8
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 08 Mar 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 08 Mar 2019.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Industry Biotechnology SGX 1,988.407 7.343 9.738 0.6940 4.744
Foreign Listing (Others) SGX 6,854.104 14.600 14.967 1.5403 3.329
Medical & Biotechnology SGX 958.457 22.468 25.696 1.3802 1.883
Local Peer Suntar Eco-City^ SGX 18.828 - - 1.1359 -
Local Peer QT Vascular SGX 8.941 0.222 - 0.5263 -
Global Peer AMGEN INC NASDAQ 131,231.478 15.634 16.268 12.0099 2.533
Global Peer CSL ASX 124,695.694 46.478 46.478 16.6635 0.966
Global Peer GILEAD SCIENCES INC NASDAQ 82,323.311 15.091 30.569 3.9955 3.551
Global Peer CELGENE CORP NASDAQ 78,302.774 19.353 13.317 6.4783 -
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 53,950.070 25.735 25.166 10.2696 -
Global Peer BIOGEN INC NASDAQ 50,933.363 11.496 9.440 3.6392 -
Global Peer ILLUMINA INC NASDAQ 44,979.795 54.455 46.228 10.1329 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,865.336 15.491 17.659 3.6047 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 24,218.966 76.642 22.592 5.1020 0.783
Other Global Peers ALEXION PHARMACEUTICAL INC (NASDAQ), SEATTLE GENETICS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), BEIGENE (HKEx), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), 3SBIO (HKEx), BLUEPRINT MEDICINES CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), FIBROGEN INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), NATERA INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), XENCOR INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), INSMED INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), MOMENTA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), EPIZYME INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), VIELA BIO INC (NASDAQ), REGENXBIO INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), FRONTAGE (HKEx), ENANTA PHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), CKLIFE SCIENCES (HKEx), ARVINAS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), KARYOPHARM THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), OPKO HEALTH INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIVA BIOTECH (HKEx), INTREXON CORP (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ASCENTAGE-B (HKEx), NEXTCURE INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), AVITA MEDICAL LTD (ASX), ROCKET PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), OMEROS CORP (NASDAQ), KURA ONCOLOGY INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), ASCLETIS-B (HKEx), RUBIUS THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), SINOMAB BIO-B (HKEx), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), TRANSLATE BIO INC (NASDAQ), XBIOTECH INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MEIRAGTX HOLDINGS PLC (NASDAQ), AGENUS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), KADMON HLDGS INC (NYSE), PROGENICS PHARMACEUTICALS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), SYNTHORX INC (NASDAQ), IMMUNOGEN INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), ESSEX BIO-TECH (HKEx), SINOVAC BIOTECH LTD (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AVROBIO INC (NASDAQ), DERMIRA INC (NASDAQ), MACROGENICS INC (NASDAQ), ARDELYX INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), LEXICON PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), COMPUGEN (NASDAQ), BELLUS HEALTH INC (NASDAQ), MEDICINOVA INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), LEE'S PHARM (HKEx), HARPOON THERAPEUTICS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), PERSONALIS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RESTORBIO INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), GERON CORP (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), KAMADA (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), DPHARMA (Bursa), SYROS PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PFENEX INC (NYSE American), ATHERSYS INC (NASDAQ), CHIASMA INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), CUE BIOPHARMA INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AFFIMED N V (NASDAQ), BBI LIFE SCI (HKEx), SOLID BIOSCIENCES INC (NASDAQ), NANOVIRICIDES INC (NYSE American), APTOSE BIOSCIENCES INC (NASDAQ), UNI-BIO GROUP (HKEx), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), ENZO BIOCHEM INC (NYSE), IVERIC BIO INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), MERSANA THERAPEUTICS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IMV INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), SESEN BIO INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), FORTRESS BIOTECH INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), CHIMERIX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), NANTKWEST INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), PHYLOGICA LIMITED (ASX), AVEO PHARMACEUTICALS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), IMUGENE LIMITED (ASX), VBI VACCINES INC CDA (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), COHBAR INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), AXCELLA HEALTH INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ARAVIVE INC (NASDAQ), SYNLOGIC INC (NASDAQ), IMMUTEP LTD (ASX), VACCINEX INC (NASDAQ), VERASTEM INC (NASDAQ), TREVENA INC (NASDAQ), CEL-SCI CORP (NYSE American), T2 BIOSYSTEMS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERMILLION INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), EQUILLIUM INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), INFLARX N V (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ORTHOCELL LIMITED (ASX), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ORGENESIS INC (NASDAQ), CURIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), PORT (SET), CT ENTERPRISE (HKEx), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), DIAMEDICA THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIONOMICS LTD (ASX), EVOGENE LTD (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), ITERUM THERAPEUTICS PLC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), REGENT PACIFIC (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), SAVARA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIOTRON (ASX), ZAFGEN INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), MEMPHASYS LTD (ASX), INVEX THERAPEUTICS LTD NPV (ASX), BIOCARDIA INC (NASDAQ), BIOSINO BIO-TEC (HKEx), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CONTRAFECT CORP (NASDAQ), ORAGENICS INC (NYSE American), ALIMERA SCIENCES INC (NASDAQ), EXTRAWELL PHAR (HKEx), MIRAGEN THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ISORAY INC (NYSE American), SEELOS THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), SOLIGENIX INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), SENESTECH INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IBIO INC (NYSE American), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), LEAP THERAPEUTICS INC (NASDAQ), IMMURON LIMITED (ASX), BIOCEPT INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), VAXART INC (NASDAQ), TOCAGEN INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), PATRYS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), CELLMID LIMITED (ASX), PRECIPIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), ADALTA LTD (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), REGENEUS LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), TROVAGENE INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 20 ORD SHS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), MEGASUN (Bursa), ADVAXIS INC (NASDAQ), OCUGEN INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), ARCA BIOPHARMA INC (NASDAQ), HAO WEN HLDGS (HKEx), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), BIOXYNE LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), MGRC (Bursa), CAPRICOR THERAPEUTICS INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), TRILLIUM THERAPEUTICS INC (NASDAQ), MEDIBIO LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), TBG DIAGNOSTICS LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), NANOLLOSE LTD (ASX), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), BPH ENERGY LIMITED (ASX), SENECA BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), OPGEN INC (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.19 MB)
Part 2(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
15 Nov 2019 79.970 79.970 79.970 79.970 - -
14 Nov 2019 79.970 79.970 79.970 79.970 - -
13 Nov 2019 79.970 79.970 79.970 79.970 - -
12 Nov 2019 79.970 79.970 79.970 79.970 - -
11 Nov 2019 79.970 79.970 79.970 79.970 - -
08 Nov 2019 79.970 79.970 79.970 79.970 - -
07 Nov 2019 79.970 79.970 79.970 79.970 - -
06 Nov 2019 79.970 79.970 79.970 79.970 - -
05 Nov 2019 79.970 79.970 79.970 79.970 - -
04 Nov 2019 79.970 79.970 79.970 79.970 - -
01 Nov 2019 79.970 79.970 79.970 79.970 - -
31 Oct 2019 79.970 79.970 79.970 79.970 - -
30 Oct 2019 79.970 79.970 79.970 79.970 - -
29 Oct 2019 79.970 79.970 79.970 79.970 - -
25 Oct 2019 79.970 79.970 79.970 79.970 - -
24 Oct 2019 79.970 79.970 79.970 79.970 - -
23 Oct 2019 79.970 79.970 79.970 79.970 - -
22 Oct 2019 79.970 79.970 79.970 79.970 - -
21 Oct 2019 79.970 79.970 79.970 79.970 - -
18 Oct 2019 79.970 79.970 79.970 79.970 - -
17 Oct 2019 79.970 79.970 79.970 79.970 - -
16 Oct 2019 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(04 Nov 2019 to 15 Nov 2019)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(18 Oct 2019 to 01 Nov 2019)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(20 Sep 2019 to 17 Oct 2019)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.